Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Atopic Dermatitis: Update Bulletin #1 [December 2018]

Product Code:
596201058
Publication Date:
December 2018
Format:
PDF
Price:
$1,315

This edition presents key opinion leader (KOL) views on recent developments in the atopic dermatitis (AD) market. Topics covered include: Galderma announcing positive results from a Phase IIb dose-ranging study of nemolizumab in adult patients with moderate-to-severe AD; DS Biopharma announcing that oral treatment with DS107 reversed the molecular signature of AD patients in a Phase IIb trial involving 319 patients with moderate-to-severe AD (ADvance study); and XBiotech announcing that it had completed enrolment in its Phase II, open-label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate-to-severe AD.

Business Questions:

• What are the experts’ reactions to the Phase IIb dose-ranging study of nemolizumab?
• According to KOLs, how viable is nemolizumab as a future treatment for AD?
• What do KOLs think of the DS107 biomarker data?
• What are the experts’ opinions on the future product positioning of DS107?
• What is the potential of bermekimab’s mechanism of action?
• What concerns do KOLs have regarding bermekimab?
• What are the key efficacy endpoints that need to be utilised in future trials?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved